{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T23:46:37Z","timestamp":1777506397200,"version":"3.51.4"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.leukres.2021.106575","type":"journal-article","created":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T10:35:49Z","timestamp":1617186949000},"page":"106575","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["CUDC-101 enhances the chemosensitivity of gemcitabine-treated lymphoma cells"],"prefix":"10.1016","volume":"106","author":[{"given":"Hongyan","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rihua","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meiying","family":"Ji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheng-Yu","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2021.106575_bib0005","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.crvi.2005.12.006","article-title":"Monoclonal antibody as therapy for malignant lymphomas","volume":"329","author":"Coiffier","year":"2006","journal-title":"CR Biol"},{"key":"10.1016\/j.leukres.2021.106575_bib0010","first-page":"217","article-title":"CHOP chemotherapy as standard therapy for treatment of patients with diffuse histiocytic lymphoma","author":"Fisher","year":"1990","journal-title":"Important Adv. Oncol."},{"key":"10.1016\/j.leukres.2021.106575_bib0015","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1200\/JCO.1995.13.10.2530","article-title":"Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin\u2019s lymphoma using CHOP versus CNOP chemotherapy","volume":"13","author":"Sonneveld","year":"1995","journal-title":"J. Clin. Oncol."},{"issue":"Suppl 1","key":"10.1016\/j.leukres.2021.106575_bib0020","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1007\/s00259-003-1157-6","article-title":"Therapy of non-Hodgkin\u2019s lymphoma","volume":"30","author":"Coffey","year":"2003","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"1","key":"10.1016\/j.leukres.2021.106575_bib0025","doi-asserted-by":"crossref","first-page":"0","DOI":"10.1016\/j.canlet.2008.08.016","article-title":"HDAC family: What are the cancer relevant targets?","volume":"277","author":"Witt","year":"2009","journal-title":"Cancer Lett."},{"key":"10.1016\/j.leukres.2021.106575_bib0030","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1002\/cncr.30100","article-title":"Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma","volume":"122","author":"Nieto","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2021.106575_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(15)00023-X","article-title":"Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b\/2 study","volume":"2","author":"Dupuis","year":"2015","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.leukres.2021.106575_bib0040","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1002\/ajh.25010","article-title":"A phase I\/II trial of vorinostat (SAHA) in combination with rituximab-CHOP in patients with newly diagnosed advanced stage diffuse large B-cell lymphoma (DLBCL)","volume":"93","author":"Persky","year":"2018","journal-title":"Am. J. Hematol."},{"issue":"7","key":"10.1016\/j.leukres.2021.106575_bib0045","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1158\/1078-0432.CCR-14-2820","article-title":"A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma","volume":"21","author":"Galloway","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.leukres.2021.106575_bib0050","first-page":"2402","article-title":"Antitumor activity of the novel HDAC inhibitor CUDC-101 combined with gemcitabine in pancreatic cancer","volume":"8","author":"Ji","year":"2018","journal-title":"Am. J. Cancer Res."},{"issue":"6","key":"10.1016\/j.leukres.2021.106575_bib0055","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1111\/bjh.14473","article-title":"How I manage peripheral T-cell lymphoma, not otherwise specified and angioimmunoblastic T-cell lymphoma: current practice and a glimpse into the future","volume":"176","author":"Schmitz","year":"2017","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2021.106575_bib0060","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1002\/ijc.22571","article-title":"Apoptotic effect of 3,4-dihydroxybenzoic acid on human gastric carcinoma cells involving JNK\/p38 MAPK signaling activation","volume":"120","author":"Lin","year":"2007","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.leukres.2021.106575_bib0065","doi-asserted-by":"crossref","first-page":"37","DOI":"10.4137\/JCD.S11034","article-title":"Crosstalk between apoptosis and autophagy: molecular mechanisms and therapeutic strategies in cancer","volume":"6","author":"El-Khattouti","year":"2013","journal-title":"J. Cell Death"},{"key":"10.1016\/j.leukres.2021.106575_bib0070","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/nrc2664","article-title":"Targeting PI3K signalling in cancer: opportunities, challenges and limitations","volume":"9","author":"Engelman","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.leukres.2021.106575_bib0075","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/nature11083","article-title":"A unifying model for mTORC1-mediated regulation of mRNA translation","volume":"485","author":"Thoreen","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.leukres.2021.106575_bib0080","first-page":"3921","article-title":"UNBS5162 induces growth inhibition and apoptosis via inhibiting PI3K\/AKT\/mTOR pathway in triple negative breast cancer MDA-MB-231 cells","volume":"16","author":"Yue","year":"2018","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.leukres.2021.106575_bib0085","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/nature10912","article-title":"The translational landscape of mTOR signalling steers cancer initiation and metastasis","volume":"485","author":"Hsieh","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.leukres.2021.106575_bib0090","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/nrc2664","article-title":"Targeting PI3K signalling in cancer: opportunities, challenges and limitations","volume":"9","author":"Engelman","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.leukres.2021.106575_bib0095","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/nature11083","article-title":"A unifying model for mTORC1-mediated regulation of mRNA translation","volume":"485","author":"Horeen","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.leukres.2021.106575_bib0100","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.hoc.2008.07.002","article-title":"Diffuse large B-cell lymphoma","volume":"22","author":"Friedberg","year":"2008","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"10.1016\/j.leukres.2021.106575_bib0105","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1182\/asheducation-2017.1.284","article-title":"Tailoring front-line therapy in diffuse large B-cell lymphoma: who should we treat differently?","volume":"2017","author":"Davies","year":"2017","journal-title":"Hematol Am Soc Hematol Educ Program."},{"key":"10.1016\/j.leukres.2021.106575_bib0110","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/S1470-2045(00)00324-7","article-title":"New therapies, new directions: advances in the systemic treatment of metastatic colorectal cancer","volume":"2","author":"Holen","year":"2001","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.leukres.2021.106575_bib0115","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1159\/000495283","article-title":"Efficacy of gemcitabine as salvage therapy for relapsed and refractory aggressive non-hodgkin lymphoma","volume":"141","author":"Zlotnick","year":"2019","journal-title":"Acta Haematol."},{"issue":"2","key":"10.1016\/j.leukres.2021.106575_bib0120","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1093\/neuonc\/nox134","article-title":"Selective BCL-xL inhibition promotes apoptosis in combination with MLN8237 in medulloblastoma and pediatric glioblastoma cells","volume":"20","author":"Levesley","year":"2017","journal-title":"Neuro Oncol"},{"issue":"11","key":"10.1016\/j.leukres.2021.106575_bib0125","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1038\/nm.3388","article-title":"The quest to overcome resistance to EGFR-targeted therapies in cancer","volume":"19","author":"Chong","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.leukres.2021.106575_bib0130","first-page":"3921","article-title":"UNBS5162 induces growth inhibition and apoptosis via inhibiting PI3K\/AKT\/mTOR pathway in triple negative breast cancer MDA-MB-231 cells","volume":"16","author":"Yue","year":"2018","journal-title":"Exp. Ther. Med."},{"issue":"7","key":"10.1016\/j.leukres.2021.106575_bib0135","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1158\/1078-0432.CCR-14-2034","article-title":"Idelalisib: first-in-Class PI3K Delta inhibitor for the treatment of chronic lymphocytic leukemia, small lymphocytic leukemia, and follicular lymphoma","volume":"21","author":"Yang","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.leukres.2021.106575_bib0140","first-page":"1","article-title":"The molecular pathogenesis of mantle cell lymphoma","author":"Vogt","year":"2016","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.leukres.2021.106575_bib0145","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1021\/jm901453q","article-title":"Discovery of 7- (4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer","volume":"53","author":"Cai","year":"2010","journal-title":"J. Med. Chem."},{"issue":"5","key":"10.1016\/j.leukres.2021.106575_bib0150","doi-asserted-by":"crossref","first-page":"0","DOI":"10.1016\/j.cdip.2004.04.006","article-title":"Recent advances in the understanding of aggressive B-cell lymphomas","volume":"10","author":"Jack","year":"2004","journal-title":"Curr. Diagn. Pathol."},{"issue":"January 143","key":"10.1016\/j.leukres.2021.106575_bib0155","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/j.ejmech.2017.10.021","article-title":"Dual or multi-targeting inhibitors: the next generation anticancer agents","volume":"1","author":"Raghavendra","year":"2018","journal-title":"Eur. J. Med. Chem."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521262100076X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521262100076X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:01:05Z","timestamp":1758934865000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014521262100076X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":31,"alternative-id":["S014521262100076X"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2021.106575","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CUDC-101 enhances the chemosensitivity of gemcitabine-treated lymphoma cells","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2021.106575","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106575"}}